文献速递角膜与眼表疾病

富血小板血浆注射治疗重度干眼的随机前瞻性临床试验

Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye.
PubMed 文献 · Br J Ophthalmol · 2018-07-03

这项前瞻性干预研究纳入干燥综合征相关重度干眼患者,干预组接受富血小板血浆(PRP)注射联合透明质酸,对照组仅用透明质酸。结果显示PRP组在角膜染色、Schirmer试验和泪膜破裂时间等主要指标上均优于对照组,且主观OSDI改善,提示PRP注射安全有效。

要点

  • PRP注射联合透明质酸在重度干眼患者中改善角膜染色、Schirmer值和TBUT。
  • PRP组第90天Schirmer值从5.6±0.7增至9.0±1.1 mm,TBUT从4.0±0.4增至6.4±0.4 s。
  • PRP注射安全有效,主观OSDI改善,优于单用透明质酸。

核心结论

  • PRP注射在改善泪液参数和主观参数方面安全有效,在重度干眼患者管理中优于单用透明质酸。

研究设计与样本

  • 前瞻性干预研究纳入干燥综合征相关重度干眼患者,干预组15例接受PRP注射(第0、30、60、90天)联合透明质酸每日5次,对照组15例仅用透明质酸每日5次。
  • 在基线和第30、60、90天测量主要结局(Oxford分类角膜染色、Schirmer试验、泪膜破裂时间)和次要结局(OSDI、治疗依从性)。

主要发现

  • 干预组所有主要结局指标均较对照组改善,包括角膜染色减少(p<0.001)。
  • 第90天干预组平均Schirmer值从5.6±0.7增至9.0±1.1 mm,TBUT从4.0±0.4增至6.4±0.4 s。
  • 主观OSDI值也观察到改善。

临床怎么用

  • 对于干燥综合征相关重度干眼患者,可考虑PRP注射联合透明质酸作为新型替代治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the effectiveness of platelet-rich plasma (PRP) injections in the treatment of severe dry eye. METHODS: This prospective, intervention study included patients with severe dry eye who had been diagnosed with Sjogren syndrome. Patients were divided into two groups. The intervention group received PRP (n=15) injections on days 0, 30, 60 and 90, as well as hyaluronic acid five times per day. The comparison group received hyaluronic acid (n=15) five times per day. Subjects were measured at baseline and at 30, 60 and 90 days. The primary outcome measures were changes in corneal staining according to the Oxford classification, results of the Schirmer test and tear break-up time (TBUT). The secondary outcome measures were changes in the Ocular Surface Disease Index (OSDI) and treatment compliance. RESULTS: All subjects completed the study. The intervention group showed improvements in all primary outcome measures when compared with the control group, including a reduction in corneal staining (p<0.001), increase in the mean Schirmer value from 5.6±0.7 to 9.0±1.1 mm, and an increase in TBUT from 4.0±0.4 to 6.4±0.4 s at day 90. An improvement in subjective OSDI values was also found. CONCLUSION: PRP injection is safe and effective in improving tear parameters as well as subjective parameters, and was found to be superior to hyaluronic acid alone in the management of patients with severe dry eye. This represent a novel alternative treatment for severe dry eye. TRIAL REGISTRATION NUMBER: NCT02257957.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Avila MY, Igua AM, Mora AM, et al. Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye. Br J Ophthalmol. 2018. PMID: 29970389. doi:10.1136/bjophthalmol-2018-312072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。